NanoViricides, Inc. (NNVC.PK) Submits DengueCide Orphan Drug Designation Application to the FDA for Dengue and Dengue Hemorrhagic Fever
6/10/2013 9:54:38 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development (OOPD) of the US FDA for DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. The Company previously engaged the consulting firm Cote´ Orphan Consulting (COC), headed by Dr. Tim Cote´, to assist with the orphan drug application. The Company, in consultation with COC, has determined that its current lead DengueCide™ drug candidate is eligible for orphan drug status application in the USA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by